No Data
No Data
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), 4D Molecular Therapeutics (FDMT) and Cullinan Management (CGEM)
Buy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising Pipeline
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag